Introduction: The UK Renal Association clinical practice guidelines include clinical performance measures for biochemical variables in dialysis patients. The UK Renal Registry (UKRR) annually audits dialysis centre performance against these measures as part of its role in promoting continuous quality improvement. Methods: Cross sectional performance analyses were undertaken to compare dialysis centre achievement of clinical audit measures for prevalent haemodialysis (HD) and peritoneal dialysis (PD) cohorts in 2013. The biochemical variables studied were phosphate, adjusted calcium, parathyroid hormone and bicarbonate. In addition, longitudinal analyses were performed (2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013) to show changes in achievement of clinical performance measures over time. Results: Fifty-seven percent of HD and 62% of PD patients achieved a phosphate within the range recommended by the RA clinical practice guidelines. Seventy-eight percent of HD and of PD patients had adjusted calcium between 2.2-2.5 mmol/L. Fifty-seven percent of HD and 63% of PD patients had parathyroid hormone between 16-72 pmol/L. Fifty-nine percent of HD and 79% of PD patients achieved the audit measure for bicarbonate. There was significant inter-centre variation for all variables studied. Conclusions: The UKRR consistently demonstrates significant inter-centre variation in achievement of biochemical clinical audit measures. Understanding the causes of this variation is an important part of improving the care of dialysis patients in the UK. 
Introduction
The UK Renal Registry (UKRR) collects routine biochemical data from clinical information systems in renal centres in England, Wales and Northern Ireland and receives data from Scotland via the Scottish Renal Registry. Annual cross sectional analyses are undertaken on some of these variables to determine centre level performance against national (Renal Association (RA)) clinical performance measures [1] . This enables UK renal centres to compare their own performance against each other and to the UK average performance. Currently the 5th edition of the UK Renal Association clinical practice guidelines is in practice [1] . This edition commenced in a graded manner in 2009 and includes an expanded number of guideline modules compared to previous editions.
Audit measures for kidney disease increasingly include tighter specification limits in conjunction with a growing evidence base. Out of range observations (e.g. hyperphosphataemia and hypophosphataemia) need to be interpreted cautiously as they may relate to different clinical problems or population characteristics. These will therefore require different strategies to improve centre performance of clinical audit measures. Summary statistical data have been provided to enhance understanding of the population characteristics of each centre and longitudinal analyses to demonstrate changes over time.
Data are also available on the UKRR data portal at www.renalregistry.org. Table 8 .1 lists the recommended biochemical based audit measures from the RA which are relevant to the dialysis population. Several of the audit measures are not currently reported by the UKRR in its annual report; the reasons behind this are varied, but predominantly relate to a high proportion of incomplete data or that the relevant variable is not currently within the specified UKRR dataset. Over time it is hoped to work with the renal community to improve reporting across the range of recommended standards.
Methods
The analyses presented in this chapter relate to biochemical variables in the prevalent dialysis cohort in England, Wales and Northern Ireland in 2013. Scotland is also included in analyses of phosphate control. The cohort studied were patients prevalent on dialysis treatment on 31st December 2013. Patients receiving dialysis for less than 90 days and those who had changed modality or renal centre in the last 90 days were excluded. Haemodialysis (HD) and peritoneal dialysis (PD) cohorts were analysed separately. A full definition of the cohort including inclusion and exclusion criteria is available in appendix B (www.renalreg.org).
The biochemical variables analysed in this chapter were serum phosphate, calcium, parathyroid hormone and bicarbonate. The method of data collection and validation by the UKRR has been previously described [2] . In brief, for each quarter of 2013 the UKRR extracted biochemical data electronically from clinical information systems in UK dialysis centres. The UKRR does not currently collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. Scottish centres have only been included in analyses relating to phosphate control, with data for their prevalent dialysis cohort being supplied directly by the Scottish Renal Registry. The audit measure used for serum phosphate was 1.1-1.7 mmol/L in both the HD and PD cohorts [1, 3] . For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, a formula in widespread use was used to calculate adjusted calcium [4] . The audit measure for adjusted calcium depends on the local reference range [3] . For the purposes of these analyses, the UKRR has used the RA guideline standard of adjusted calcium between 2.2-2.5 mmol/L as the audit measure [3] . There are also a variety of methods and reference ranges in use to measure parathyroid hormone (PTH). To enable some form of comparative audit the UKRR has used 2-9 times the median upper limit of the reference range (8 pmol/L) as the audit measure in line with the 5th edition of the RA clinical practice guidelines and KDIGO 2009 guidance [3, 5] . This equates to a PTH range of 16-72 pmol/L. The audit measure used for serum bicarbonate in the HD cohort was 18-24 mmol/L as per the updated haemodialysis guidelines and in the PD cohort was 22-30 mmol/L. A summary of the current RA audit measures for these variables and conversion factors to SI units are given in table 8.2 .
Quarterly values were extracted from the database for the last two quarters for calcium, phosphate and bicarbonate and the last three quarters for PTH. Patients who did not have these data were excluded from the analyses. Data completeness was analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots and tables showing centre level performance. Data were also excluded from plots and tables when there were less than 20 patients with data both at centre or country level. These data were analysed to calculate summary descriptive statistics (maximum, minimum, means with the corresponding standard deviation, medians and interquartile ranges). Where applicable, the percentage achieving the Renal Association standard or other surrogate clinical performance measure was also calculated.
The simultaneous control of all three components of bone and mineral disorder (BMD) parameters were analysed in combination. The proportion of patients with control of none, one, two or three parameters are presented. For the purpose of these analyses a corrected calcium between 2.2-2.5 mmol/L, a phosphate level being maintained at or below 1.7 mmol/L and a PTH level being at or below 72 pmol/L, were evaluated in combination.
Centres report several biochemical variables with different levels of accuracy, leading to problems in comparative evaluation.
For example, in the case of serum bicarbonate, data can be submitted as integer values but some centres submit data to one decimal place. All data has been rounded in an attempt to make all centres more comparable.
The number preceding the centre name in each figure indicates the percentage of missing data for that centre. Funnel plot analyses were used to identify 'outlying centres' [6] . The percentage within range for each standard was plotted against centre size along with the upper and lower 95% and 99.9% limits. Centres can be identified on these plots by looking up the number of patients treated in each centre provided in the relevant table and finding this value on the x-axis. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2003 to 2013 and were recalculated for each previous year using the rounding procedure.
All data are presented unadjusted for case-mix.
Results

Mineral and bone variables Phosphate
In 2013 the following Renal Association clinical practice guideline regarding phosphate management was applicable:
Guideline 3.2 CKD-MBD: Serum phosphate in dialysis patients ' We suggest that serum phosphate in dialysis patients, measured before a ''short-gap'' dialysis session in haemodialysis patients, should be maintained between 1.1 and 1.7 mmol/L (2C)' [3] .
The data completeness for serum phosphate across the UK was 97% for HD patients and 98% for PD patients although there was considerable variation between centres (tables 8.3, 8.5) . The individual centre means and standard deviations are shown in tables 8.3 and 8.5. Fifty-seven percent (95% CI 56-58%) of HD patients and 62% (95% CI 60-63%) of PD patients achieved a phosphate level within the target range specified by the RA clinical audit measure (tables 8.4, 8.6 ). The proportion of HD patients with hyperphosphataemia was 30% and the proportion with hypophosphataemia was 13% ( 'We suggest that serum calcium, adjusted for albumin concentration, should be maintained within the normal reference range for the laboratory used, measured before a ''short-gap'' dialysis session in haemodialysis patients. Ideally, adjusted serum calcium should be maintained between 2.2 and 2.5 mmol/L, with avoidance of hypercalcaemic episodes (2D)' [3] .
In 2013, the data for adjusted calcium was 97% complete for HD patients and 98% complete for PD patients overall, although there was between centre variation (tables 8.7, 8.9). Seventy-eight percent (95% CI 78-79%) of HD patients and 78% of PD (95% CI Similar to that seen in the earlier presented phosphate analyses, there was significant between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure (figures 8.6-8.10). There was greater variation in the proportion of patients within range for adjusted calcium than phosphate, most notably for HD patients. The funnel plot shows a greater number of centres outlying the three standard deviation limit indicating over dispersion in the data, possibly due to differences in calcium adjustment factors between centres.
The changes in the percentages above, below and within range for the period 2003 to 2013 for England, Northern Ireland and Wales combined are shown in figure 8.10. The percentage of patients achieving the audit standard for calcium appears to have plateaued for both HD and PD patients in recent years. As with the phosphate data, this overall plateau masks substantial deterioration in a few centres achieving the standard this year (Carlisle, Antrim, Wrexham for HD patients; London West, Newcastle, Cardiff for PD patients) that has been countered by improvements in other centres.
Parathyroid hormone
At the beginning of 2013 the following RA guideline for PTH applied: Guideline 4.2.1 CKD-MBD: Target range of serum PTH in patients on dialysis ' We suggest that the target range for parathyroid hormone measured using an intact PTH assay should be between 2 and 9 times the upper limit of normal for the assay used (2C)' [3] .
The data for parathyroid hormone were 93% complete for HD patients and 90% for PD patients overall, In 2013, the proportion of HD patients with a parathyroid hormone above the upper limit of the range (.72 pmol/L) was 17% and the proportion with parathyroid hormone below the lower limit of the range was 26%, very similar to aggregate level results in 2012. The proportion of PD patients with parathyroid hormone above the upper limit of the range was 13% and the proportion below the lower limit of the range was 24% (tables 8.12, 8.14, figures 8.11-8.14). Again there was significant between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure.
There was no substantial variation in attainment of the standard for HD patients but there was deterioration for some PD centres (Birmingham Heartlands, Basildon, Newcastle, Portsmouth) where increases in patients both below and above the audit range were seen. Control of none of the parameters of BMD was found in 1.9% of HD patients and 1.6% of PD patients across England, Wales and Northern Ireland cumulatively. Control of one parameter was reported in 13.0% of HD and 12.5% of PD patients; of two parameters in 35.9% of HD and 35.8% of PD patients; and of all three parameters in 49.3% of HD and 50.1% of PD patients (tables 8.15, 8.16 ).
Figures 8.18 and 8.19 are funnel plots of all centres who contributed data to these analyses based on the size of the centre and the percentage of patients achieving the control of all three BMD parameters. In HD patients, there was a negative trend observed between centre size and the simultaneous control of all three BMD parameters as identified in this analysis. No such trend was observed in PD patients, perhaps because PD centres are all of a small size.
Bicarbonate
In 2013 the following Renal Association clinical practice guidelines regarding bicarbonate management were applicable:
Haemodialysis Guideline 6.3: Pre-dialysis serum bicarbonate concentrations 'We suggest that pre-dialysis serum bicarbonate concentrations, measured with minimum delay after venepuncture, should be between 18 and 24 mmol/l [7] .
Peritoneal Dialysis Guideline 6.2 -PD: Metabolic factors ' We recommend that plasma bicarbonate should be maintained within the normal range' [8] . As in previous years, between centre variation was observed in attainment of the audit standard for both figure 8 .24. Sample processing, case-mix, differences in dialysis, residual renal function and oral bicarbonate prescriptions may all contribute to the variation observed.
Conclusions
The UKRR has consistently demonstrated between centre variation in achievement of audit measures for bone and mineral parameters but little is understood about the causes of this 'centre effect'. The complexity of the clinical processes required to manage mineral and bone disorders is probably further confounded by case-mix. In the future, with centres moving to newer IT systems, medications used in the management of bone and mineral diseases may become available to aid in better analyses of these parameters.
Additionally, it is important to consider data quality and the potential for measurement error particularly in light of the variability in assay methods, for example for parathyroid hormone. However, detecting these centre level differences is an important step in understanding the factors associated with variation in performance. Some specifics for consideration are highlighted below.
Bone Mineral Variables
Observational data support that hyperphosphataemia is associated with increased mortality in dialysis patients but the data linking calcium and parathyroid hormone to patient survival are less clear [9] [10] [11] [12] [13] . A cohort study has however suggested that simultaneous achievement of all three audit measures does appear to be associated with better patient outcomes [14] .
Possible issues relating to calcium measures
The current RA guidelines are based upon measures of adjusted serum calcium [3] . A variety of formulae have been proposed to permit calculation of the 'adjusted' total calcium (i.e. an estimation of the expected total calcium were the serum albumin normal) from the total calcium and albumin concentration, but there are no data to support the use of mathematical corrections of serum calcium amongst patients with ERF. This topic was discussed in detail in the 2009 annual report and most of the shortcomings remain [15] . However, the ongoing restructuring of pathology into a smaller number of services together with harmonisation should increase measurement uniformity across laboratories and hence renal centres. UK laboratories are still in the process of adopting the guidelines to harmonise albumin-adjusted calcium reference ranges to 2.2-2.6 mmol/L using method-specific adjustment equations normalised to a mean calcium of 2.4 mmol/L. Until this process is complete, differences between laboratories in the reported adjusted calcium are likely to continue. Meanwhile, centres must work with their laboratories to ensure that
